What is it? Why is it important?

Lessons learned are important experiences and observations gathered during study planning and conduct.

 

These lessons could be useful to improve the management of subsequent studies. The aim would be to repeat experiences that were fruitful, and avoid those experiences that were problematic.

 

Thus, already during study planning and conduct, but certainly upon study termination, a retrospective evaluation of the study should be performed. Experiences both positive and negative gathered during earlier studies could greatly benefit the successful implementation of future studies.

What do I need to do?

As a SP-INV, , assess lessons learned regarding the:

Budget:

Participant recruitment:

  • Were adequate eligible participants available?
  • Were timelines and processes respected?

Resources and processes:

Biobanking

Study oversight

  • Was the division of tasks and responsibilities clear? What strategies were helpful, which ones just added extra unnecessary workload?

More

As a SP-INV or Site-INV, upon study conclusion:

  • Ask yourself, which “Lessons Learned” turned out to be especially valuable in supporting the quality of the study?
  • Ask yourself, which “Lessons Learned” turned out to be especially valuable in protecting the integrity of the studies “Critical to Quality” (CtoQ) factors?
  • Provide a summary of valuable “Lessons Learned” with the aim to support a "Qualtiy by Design" (QbyD) approach in future studies. Ensure a process is in place to ensure “Lessons Learned” are incorporated during the planning process.
  • Based on “Lessons Learned” establish quality processes (e.g. SOPs, Wis) that avoid the re-occurrence of previously unwanted effects or consequences during study conduct (e.g. risks to participant right and safety and/or data quality)

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular guideline

  • 3.10 Quality management

 

ICH E8(R1) – see in particular

  • 3.1 Quality by Design of clinical studies
  • 3.2 Critical to Quality Factors

 

ISO 9001 (access liable to costs) – see in particular section

  • QMS Requirements
Abbreviations
  • CtoQ – Critical to Quality
  • CTU – Clinical Trials Unit
  • ICH – International Council for Harmonisation
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • ISO – International Organization for Standardization
  • QbyD – Quality by Design
  • Site-INV – Site Investigator
  • SOP – Standard Operating Procedures
  • SP-INV – Sponsor Investigator
  • WI – Working Instructions
Completion ↦ Management ↦ Study Closure ↦ Lessons Learned
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Completion ↦ Management ↦ Study Closure ↦ Lessons Learned